The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some great points on here and be they positive or negative all outcomes are possible. For me the worrying word in any company statement is ‘potential’. It has a real negative aroma which just keeps the shareholder carrot dangling. Buy a lottery ticket today and ‘potentially’ you could win.
I prefer the confidence of a ‘we will’ statement. AIHL will be market leading and generate revenue sounds very different to AIHL could potentially be market leading and could generate profit.
Our current useless lying government certainly would not have got Brexit through had they said it would potentially do this or that. I absolutely don’t advocate telling lies but hear a real lack of confidence in Budd’s messaging.
This lack of conviction then plays through to potential buyers and investors.
And if there was even the merest whiff of a £10m deal for off GDR’s products then the sp would indeed swoop up to at least £1, probably beyond. Our problem now is that everyone knows Budd and his team can’t sell anything, nor can he be trusted when he does come out with positive statements. I think that’s why he’s uber cautious these days and plays timings down. He’s not managed to pull off one of the deals he announced were potentially on the table. He has spent a great deal in developing products and generated zero income. As such no serious investors will touch this until there is an RNS announcing a revenue-generating deal is confirmed 100%. Then funds will flow in but sadly not before, and certainly not at the behest of half a dozen childish posts on this bb saying I can feel an RNS coming today…or words to that affect.
Rather depressed about this stock. It has so much potential but Budd could already be well on the way to realising none of it. Who ever said it regarding a raise being the next news we’ll get may well end up being right. There is No way we are funded for all the new assays and keeping the show on the road for the next year or so. Unless that is Budd in his infinite wisdom decided not to spend any money on FDA submissions and applications - and therefore closing the door on the biggest single market place for any of GdR’s products. I wouldn’t put it past him but no, I think he’ll go ahead with applications for approvals and in order to do this he’ll come back to the market for another raise. He may have to purchase another £20k worth as he did last time and who knows, perhaps that will put him off doing the raise.
I think we all know now that the only thing that is going to re rate the sp is sales news , yes we make get a good spike on the sp with good news is released but to put us in a higher trading range than we are now will be sales, sales , sales . The good news is that it WILL happen , this week no, next month , no but by the end of the year is a very good possibility IMO.
Budd always said we was gonna make big ££ from pcr and had a 10 mil + deal in the pipeline that was pretty much a sure thing
They are never gonna say thanks for the raise we might get it right this time fingers crossed
Thanks Bedhead. That has indeed reminded me that we’re talking months if not years to generate revenue and maybe eventually some profit. Nothing is going to happen here in the next few days or weeks. I will come back back in 6 months and hopefully there might be something regarding ‘best practice’ as that will be a key signal for much wider adoption. The Manchester hospitals will need to use it for at least 6 months and then report on its impact and then we may get something announced by NICE that it’s a definite green light.
Key phrase used by Budd himself here is ‘medium to long term’……months and years. Not days or weeks.
We believe the company is well positioned to deliver on shareholder value; we have managed our cash position carefully and are poised to progress with our expanded portfolio.”
He thanked investors who continue to support the company as it moves further into a commercial phase.
Looking ahead, he added: “Whilst the future trajectory of the pandemic is not possible to predict, as a board we are excited about the COVID-19 point of care assay’s technical performance and unique selling points, and we remain optimistic that it has the opportunity to generate meaningful revenues for the company.
“The AIHL product is now launched and although adoption into healthcare systems will be step by step until formally recognised as being ‘best practice’, we remain confident in the business case and predict escalating adoption in the UK and abroad, and expect in the medium to long term that the assay has the potential to sustain the business through to profitable revenues.”
He said the company expects to drive value from other single target test markets and is focusing its resources on point of care opportunities that can complement AIHL in emergency care settings, and bring long term revenue growth to the business.
“This is a critical phase of the company, but we have sufficient cash resources to allow both point of care products to embed themselves and have confidence that over time we can build successful revenues streams for these and other point of care products in the future.”